Medical Economics March 26, 2025
Key Takeaways
- “Global freeloading” hinders pharmaceutical innovation by allowing other countries to benefit from U.S. research without sharing costs, impacting drug development.
- Chronic diseases like cancer and diabetes are increasing in the U.S., driving healthcare costs and necessitating new drug development.
- Americans pay significantly more for prescription drugs compared to other wealthy nations, exacerbating financial imbalances.
- Proposed solutions include most-favored nation pricing, international pricing models, and leveraging trade authority to address global freeloading.
Policy center argues patients around the world benefit when Americans pay more than their fair share for research and medicines.
More Americans are suffering from more chronic diseases, but “global freeloading” is clogging the research and development pipeline for new prescription medicines to treat them,...
Today's Sponsors
Today's Sponsor